Jazz Pharmaceuticals plc : In an upward trend
Entry price | Target | Stop-loss | Potential |
---|
$69.82 |
$76.5 |
$68.43 |
+9.57% |
---|
Jazz Pharmaceuticals is still well oriented and is going to new highs.
Regarding the fundamentals, the firm is financially healthy with no financial leverage because of a cash surplus expected for 2013. Moreover the group has a very high operating margin at 56.7% for 2013, sign of a valuable business.
Graphically, the security is up 29% since the 1st January. It seems able to continue this uptrend supported by moving averages and will soon test the USD 70.8 mid-term resistance. We anticipate a crossing of this level, given the upward orientation of the stock in the medium and long term.
Exceeding the technical line at USD 70.9 would point to ambitious upward targets. In this case, market participants could buy this stock with an initial target of USD 76.5. If investors reduce long-side exposure for profit-taking, a bearish trend would happen below USD 68.5 and so this strategy would be invalidated.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.